PR1 leukemia peptide vaccine

BIOLOGICAL3 trials

Sponsors

National Cancer Institute (NCI), The Vaccine Company

Conditions

Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia in RemissionChronic Phase Chronic Myelogenous LeukemiaLeukemiaMyelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRefractory Anemia With Excess BlastsRefractory Anemia With Excess Blasts in Transformation

Phase 1

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

CompletedNCT00004918

National Cancer Institute (NCI)Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia +4

Start: 1999-12-31Target: 69Updated: 2013-01-07

Phase 2

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

The Vaccine CompanyMyelodysplastic Syndromes

Start: 2007-01-31Target: 30Updated: 2014-01-06

Phase 3

Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission

The Vaccine CompanyLeukemia

Start: 2005-05-31Target: 244Updated: 2014-01-06